StockData

Monte Rosa Therapeutics vs Invivyd

GLUE and IVVD side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How GLUE and IVVD compare

Monte Rosa Therapeutics is the larger company, worth 5.1 times as much as Invivyd ($774M against $151M).

Invivyd grew revenue faster over the last twelve months (26.3% versus −83.9% for Monte Rosa Therapeutics).

Invivyd keeps more of each dollar of sales as profit, with a net margin of −184% compared with −561% at Monte Rosa Therapeutics.

Invivyd scores higher on the StockData Score (9 against 7 for Monte Rosa Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricGLUEIVVD
Size and price
Market cap$774M$151M
Share price$9.07$0.513
Change, 1 year−36.8%−78.2%
Change, 5 years−55.9%−98.0%
Beta (5Y)2.022.53
Employees150122
StockData Score
Total score79 (better)
Valuation score13 (better)
Growth score01 (better)
Performance score1 (better)0
Health score55
Dividend score00
Valuation
P/S26.9×2.6× (better)
P/B1.6×0.8× (better)
FCF yield−4.1% (better)−72.6%
Fair value$6.54$0.978
Margin of safety−38.7%47.6% (better)
Growth
Revenue growth (TTM)−83.9%26.3% (better)
Net income growth (TTM)−767%–
EPS growth (TTM)−707%–
Profitability
Operating margin−633%−193% (better)
Net margin−561%−184% (better)
FCF margin−112% (better)−188%
Return on equity−42.7% (better)−95.9%
Return on invested capital–−616%
Financial health
Debt / equity0.000.00
Current ratio10.58 (better)5.87
Altman Z-score1.30 (better)−4.86
Piotroski F-score55
Dividends and buybacks
Buyback yield–−0.26%
Shareholder yield0.00% (better)−0.26%
Ownership
Held by institutions109%79.0%
Held by insiders11.5%16.7%
Insider net buying, 12 months−$4.1M−$531K (better)
Superinvestors holding1–
Short interest, % of float27.6%14.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.